Trial · NCT03617536
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 | CR845 0.25 mg Oral Tablet | -3.99 | 95% Confidence Interval -4.62 to -3.36 | score on a scale | |
| Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 | CR845 0.5 mg Oral Tablet | -3.84 | 95% Confidence Interval -4.50 to -3.18 | score on a scale | |
| Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 | CR845 1 mg Oral Tablet | -4.42 | 95% Confidence Interval -5.08 to -3.76 | score on a scale | |
| Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 | Placebo Oral Tablet | -3.32 | 95% Confidence Interval -3.97 to -2.68 | score on a scale | |
| Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12 | CR845 0.25 mg Oral Tablet | -21.19 | 95% Confidence Interval -24.34 to -18.04 | score on a scale | |
| Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12 | CR845 0.5 mg Oral Tablet | -22.13 | 95% Confidence Interval -25.37 to -18.89 | score on a scale | |
| Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12 | CR845 1 mg Oral Tablet | -23.57 | 95% Confidence Interval -27.00 to -20.14 | score on a scale | |
| Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12 | Placebo Oral Tablet | -19.95 | 95% Confidence Interval -23.17 to -16.73 | score on a scale | |
| Change From Baseline in 5-D Itch Scale Score at the End of Week 12 | CR845 0.25 mg Oral Tablet | -6.17 | 95% Confidence Interval -7.10 to -5.25 | score on a scale | |
| Change From Baseline in 5-D Itch Scale Score at the End of Week 12 | CR845 0.5 mg Oral Tablet | -6.84 | 95% Confidence Interval -7.78 to -5.90 | score on a scale | |
| Change From Baseline in 5-D Itch Scale Score at the End of Week 12 | CR845 1 mg Oral Tablet | -6.97 | 95% Confidence Interval -7.97 to -5.97 | score on a scale | |
| Change From Baseline in 5-D Itch Scale Score at the End of Week 12 | Placebo Oral Tablet | -5.74 | 95% Confidence Interval -6.69 to -4.80 | score on a scale | |
Reduction of Itch Intensity as Assessed by the Proportion of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12 | CR845 0.25 mg Oral Tablet | 66.2 | 95% Confidence Interval 53.00 to 77.32 | percentage of subjects | |
Reduction of Itch Intensity as Assessed by the Proportion of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12 | CR845 0.5 mg Oral Tablet | 64.8 | 95% Confidence Interval 51.18 to 76.30 | percentage of subjects | |
Reduction of Itch Intensity as Assessed by the Proportion of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12 | CR845 1 mg Oral Tablet | 72.1 | 95% Confidence Interval 58.62 to 82.45 | percentage of subjects | |
Reduction of Itch Intensity as Assessed by the Proportion of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12 | Placebo Oral Tablet | 57.9 | 95% Confidence Interval 44.15 to 70.49 | percentage of subjects |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03617536/results